background
viral
respiratori
infect
common
worldwid
rang
complet
benign
diseas
lifethreaten
ill
symptom
unspecif
etiolog
diagnosi
rare
establish
lack
suitabl
diagnost
tool
improp
use
antibiot
common
set
detriment
light
develop
bacteri
resist
suggest
use
diagnost
test
could
reduc
antibiot
prescript
rate
object
studi
evalu
whether
access
multiplex
polymeras
chain
reaction
pcr
assay
panel
etiolog
diagnosi
acut
respiratori
tract
infect
arti
would
impact
antibiot
prescript
rate
primari
care
clinic
set
method
adult
patient
symptom
arti
prospect
includ
nasopharyng
throat
swab
analys
use
multiplex
realtim
pcr
method
target
thirteen
virus
two
bacteria
patient
recruit
outpati
unit
octob
april
sampl
collect
day
inclus
initi
visit
day
followup
visit
patient
randomis
openlabel
treatment
protocol
receiv
rapid
delay
result
follow
day
eight
twelv
day
primari
outcom
measur
antibiot
prescript
rate
initi
visit
secondari
outcom
total
antibiot
prescript
rate
studi
period
result
total
sampl
patient
randomis
fortyon
exclud
leav
patient
analysi
group
patient
randomis
rapid
result
patient
receiv
antibiot
initi
visit
compar
p
patient
delay
result
group
followup
signific
differ
group
rapid
result
group
delay
result
group
p
respect
conclus
access
rapid
method
etiolog
diagnosi
arti
may
reduc
antibiot
prescript
rate
initi
visit
outpati
set
sustain
effect
howev
seem
necessari
better
defin
follow
manag
patient
accord
result
test
warrant
investig
trial
registr
clinicaltrialsgov
identifi
acut
respiratori
tract
infect
arti
repres
major
global
health
burden
virus
caus
larg
proport
arti
distinguish
bacteri
arti
requir
antibiot
treatment
viral
arti
need
antibiot
prescript
difficult
clinic
ground
alon
caus
unnecessari
use
antibiot
highest
rate
occur
primari
care
set
excess
use
antibiot
major
implic
health
econom
importantli
develop
bacteri
resist
well
individu
patient
term
advers
event
allerg
reaction
antibioticassoci
diarrhoea
predict
valu
vital
sign
creactiv
protein
crp
xray
find
diagnos
pneumonia
requir
antibiot
low
treatment
acut
bronchiti
serv
illustr
exampl
unnecessari
use
antibiot
recommend
therapi
immun
compet
adult
includ
antibiot
treatment
yet
antibiot
found
prescrib
condit
high
rate
studi
conduct
unit
kingdom
sweden
unit
state
use
improv
diagnost
method
nucleic
acid
amplif
test
naat
includ
multiplex
realtim
polymeras
chain
reaction
rtpcr
assay
increas
recent
year
method
proven
equival
superior
convent
method
short
turnaround
time
laboratori
well
afford
clinician
abil
analys
sever
respiratori
agent
within
patient
sampl
suggest
use
naat
includ
multiplex
pcr
method
detect
respiratori
pathogen
could
reduc
antibiot
prescript
rate
present
studi
design
evalu
whether
access
multiplex
rtpcr
method
target
thirteen
virus
would
impact
antibiot
prescript
rate
arti
primari
care
set
conduct
investigatoriniti
multicentr
prospect
randomis
control
trial
adult
patient
primari
care
set
elig
criteria
particip
age
year
diagnosi
communityacquir
arti
defin
histori
least
two
follow
symptom
coryzanas
congestionsneez
sore
throatodynophagia
cough
pleurit
chest
pain
short
breath
fever
physician
found
explan
durat
less
day
exclus
criteria
includ
confirm
bacteri
infect
defin
posit
streptococcu
group
quick
test
clinic
find
correspond
bacteri
tonsil
perfor
acut
otiti
media
high
suspicion
lobar
pneumococc
pneumonia
sever
septicaemia
posit
blood
cultur
clinic
signific
bacteri
pathogen
clinic
find
correspond
septicaemia
ongo
antibiot
treatment
patient
recruit
outpati
unit
eight
primari
healthcar
centr
four
depart
infecti
diseas
sampl
collect
octob
april
sign
symptom
record
webbas
case
report
form
patient
enrol
treat
physician
day
inclus
stratifi
accord
durat
symptom
either
day
day
openlabel
nonblind
randomis
ratio
perform
mean
predefin
list
use
conceal
central
webbas
procedur
day
inclus
treat
physician
receiv
result
multiplex
pcr
analysi
either
day
follow
inclus
rapid
result
cohort
eight
twelv
day
later
delay
result
cohort
recruit
perform
sunday
thursday
pm
allow
laboratori
report
result
follow
day
nasopharyng
flock
nylon
swab
microrheolog
brescia
itali
throat
swab
specimen
collect
patient
swab
jointli
place
steril
contain
ml
sodium
chlorid
solut
sent
laboratori
day
specimen
either
analyz
directli
frozen
delay
analysi
see
randomis
mask
result
commun
webbas
case
report
form
studi
nurs
site
addit
diagnost
test
includ
throat
sputum
cultur
crp
xray
investig
left
discret
treat
physician
record
case
report
form
object
studi
evalu
whether
access
rapid
etiolog
diagnost
method
would
impact
antibiot
prescript
primari
outcom
measur
antibiot
prescript
rate
initi
visit
within
hour
thereaft
secondari
outcom
measur
total
antibiot
prescript
rate
studi
period
antibiot
prescript
initi
visit
within
hour
thereaft
record
analys
relat
access
rapid
vs
delay
result
result
rapid
result
group
provid
treat
physician
within
hour
major
patient
within
hour
patient
final
manag
patient
act
upon
given
result
pcr
assay
left
discret
treat
physician
patient
ask
return
followup
visit
eight
twelv
day
initi
visit
time
period
repres
durat
followup
studi
total
antibiot
prescript
rate
prescript
initi
visit
followup
visit
visit
record
constitut
secondari
outcom
measur
studi
prescript
antivir
medic
record
seriou
advers
event
sae
defin
death
lifethreaten
event
hospitalis
event
result
threaten
result
persist
signific
disabl
region
ethic
review
board
approv
studi
patient
provid
written
inform
consent
particip
studi
util
rtpcr
procedur
base
autom
specimen
extract
multiplex
amplif
adapt
respiratori
specimen
previous
describ
briefli
nucleic
acid
respiratori
specimen
extract
elut
volum
use
magnapur
lc
robot
roch
molecular
system
mannheim
germani
accord
total
nucleic
acid
protocol
amplifi
abi
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
reaction
volum
revers
transcript
step
cycl
twostep
pcr
perform
sampl
amplifi
six
parallel
reaction
contain
primer
probe
previous
report
modif
adenoviru
analys
separ
reaction
includ
panel
parainfluenzaviru
piv
type
influenza
viru
ifa
influenza
viru
b
ifb
human
metapneumoviru
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
enteroviru
ev
adenoviru
adv
human
coronaviru
hcov
type
along
bacteria
mycoplasma
pneumonia
chlamydophila
pneumonia
primer
probe
rtpcr
assay
design
bind
conserv
segment
target
agent
particularli
import
adv
hrv
ev
characteris
larg
number
subtyp
accuraci
adv
pcr
assay
document
heim
et
al
target
region
hrv
ev
assay
conserv
segment
untransl
region
allow
amplif
subtyp
use
previous
other
primer
probe
use
ifb
piv
type
develop
dr
lar
nielsen
copenhagen
denmark
piv
type
previous
describ
watzing
et
al
hcov
type
describ
previous
gunson
et
al
ifa
viru
modif
system
publish
ward
et
al
basi
natur
primari
outcom
measur
patient
protocol
violat
andor
miss
data
exclud
primari
analysi
predefin
analysi
plan
test
use
compar
proport
p
consid
statist
signific
studi
schedul
includ
least
patient
group
allow
statist
power
demonstr
estim
reduct
antibiot
prescript
rate
rapid
result
group
multivari
analysi
use
backward
stepwis
wald
test
logist
regress
carri
analys
factor
separ
independ
predict
posit
pcr
result
well
prescript
antibiot
spss
version
macintosh
softwar
spss
inc
chicago
il
usa
use
statist
analys
patient
flow
accord
studi
design
shown
figur
baselin
characterist
two
group
patient
randomis
rapid
vs
delay
result
shown
tabl
entir
studi
popul
antibiot
prescrib
patient
initi
visit
within
hour
thereof
group
patient
randomis
rapid
result
patient
receiv
antibiot
compar
patient
delay
pcrbase
result
group
p
see
tabl
patient
symptom
durat
day
rapid
result
group
receiv
significantli
fewer
antibiot
prescript
patient
delay
result
group
patient
receiv
initi
antibiot
treatment
test
posit
respiratori
viru
compris
three
rapid
result
group
eleven
delay
result
group
see
tabl
total
patient
return
option
followup
visit
avail
telephon
appoint
visit
n
telephon
appoint
n
compris
patient
rapid
result
group
patient
delay
result
group
total
patient
rapid
result
group
patient
delay
result
group
receiv
antibiot
treatment
either
initi
followup
visit
differ
statist
signific
p
antibiot
prescript
outsid
studi
studi
physician
allow
followup
visit
two
nineteen
patient
rapid
result
group
one
nine
patient
delay
result
group
report
ongo
antibiot
treatment
prescrib
outsid
studi
investig
report
sae
shown
tabl
patient
test
posit
one
agent
basi
multiplex
pcr
assay
perform
initi
visit
addit
patient
test
posit
two
agent
sampl
three
patient
one
viru
one
bacterium
detect
nine
patient
two
virus
detect
see
tabl
crp
level
record
patient
predefin
subgroup
analysi
reveal
patient
crp
level
mgl
patient
crp
level
mgl
patient
crp
level
mgl
patient
receiv
antibiot
treatment
initi
visit
compar
patient
group
crp
level
mgl
p
rapid
result
group
two
twentyfour
patient
crp
level
mgl
receiv
antibiot
compar
multivari
analysi
record
symptom
fever
odd
ratio
confid
interv
ci
p
pleurit
chest
pain
ci
p
remain
independ
predict
posit
pcr
result
pneumonia
c
pneumonia
exclud
analysi
report
sore
throat
ci
p
significantli
common
among
patient
neg
pcr
result
vomit
remain
symptom
associ
prescript
antibiot
initi
visit
ci
p
multivari
analysi
high
fever
common
group
patient
randomis
delay
result
patient
group
randomis
rapid
result
see
tabl
signific
differ
number
antibiot
prescript
initi
visit
group
note
see
tabl
shown
access
rapid
result
use
method
aetiolog
diagnosi
arti
outpati
set
significantli
reduc
antibiot
prescript
initi
visit
howev
effect
longer
signific
time
followup
studi
evalu
impact
access
rapid
diagnost
tool
rather
impact
actual
test
result
impli
mere
prospect
rapid
aetiolog
diagnosi
influenc
therapeut
decis
made
patient
indistinct
clinic
present
subgroup
patient
crp
level
mgl
effect
even
pronounc
among
patient
posit
pcr
result
virus
significantli
fewer
patient
rapid
result
group
receiv
antibiot
delay
result
group
result
line
reduct
antibiot
prescript
rapid
diagnost
test
ifa
viru
use
systemat
hospitalis
adult
patient
children
although
studi
evalu
impact
result
test
thu
fulli
compar
limit
studi
includ
choic
antibiot
prescript
primari
outcom
openlabel
design
might
led
perform
bia
physician
might
influenc
randomis
make
decis
whether
prescrib
antibiot
also
basi
studi
design
option
followup
visit
larg
number
patient
lost
followup
rel
short
followup
period
effect
durat
antibiot
treatment
relat
diagnosi
could
properli
evalu
influenc
antibiot
resist
advers
event
follow
antibiot
therapi
necessari
reduc
total
rate
antibiot
prescript
achiev
studi
howev
time
plan
studi
limit
prospect
data
avail
perform
multiplex
pcr
panel
diagnosi
viral
bacteri
arti
clinic
practis
possibl
defin
whether
patient
prescrib
antibiot
depend
test
result
therefor
chose
antibiot
prescript
initi
visit
straightforward
primari
outcom
measur
evalu
whether
access
test
would
effect
antibiot
prescript
rate
includ
futur
studi
algorithm
manag
patient
arti
systemat
test
bacteri
pathogen
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
conduct
studi
bacteria
may
act
potenti
respiratori
pathogen
prp
harbour
upper
respiratori
tract
extens
panel
includ
bacteri
agent
might
improv
clinic
util
test
howev
interpret
detect
bacteri
pathogen
nasopharyng
sampl
heterogen
syndrom
arti
unclear
cultur
pneumonia
nasopharynx
adult
shown
high
specif
low
sensit
diagnosi
pneumococc
pneumonia
pcrbase
detect
pneumonia
oropharynx
nasopharynx
without
codetect
commens
streptococcu
spp
pose
technic
difficulti
lieberman
et
al
report
higher
sensit
use
nasopharyng
wash
compar
nasopharyng
swab
detect
prp
keep
sampl
simpl
nasopharyng
wash
use
studi
may
constitut
studi
limit
howev
use
flock
nasopharyng
swab
probabl
yield
higher
detect
rate
previous
report
studi
cottontip
nasopharyng
swab
use
studi
popul
consist
patient
broad
spectrum
clinic
manifest
mani
mild
symptom
howev
sinc
prescript
antibiot
patient
uncommon
deliber
studi
design
previous
oosterheert
et
al
investig
impact
pcr
method
aetiolog
diagnosi
lower
rti
adult
fail
show
reduct
use
antibiot
howev
studi
includ
hospitalis
patient
end
point
regist
chang
ongo
treatment
regimen
rather
whether
make
initi
decis
prescrib
antibiot
treatment
followup
studi
longer
show
signific
differ
antibiot
use
two
studi
group
howev
sinc
larg
number
patient
lost
followup
select
patient
may
bias
moreov
physician
outsid
studi
prescrib
antibiot
patient
initi
visit
followup
visit
studi
design
accuraci
prescript
followup
could
properli
evalu
thu
result
must
interpret
caution
absenc
algorithm
determin
follow
patient
act
upon
result
pcr
test
includ
predefin
antibiot
manag
plan
observ
reduct
antibiot
use
initi
visit
may
lost
time
followup
howev
studi
repres
proof
concept
access
rapid
etiolog
diagnost
tool
may
affect
therapeut
decis
set
antibiot
prescript
rate
studi
low
recent
retrospect
studi
primari
care
patient
compar
swedish
region
record
antibiot
prescript
rate
patient
arti
patient
acut
bronchiti
patient
common
cold
low
prescript
rate
seri
could
due
partli
tendenc
adher
strictli
usual
current
guidelin
restrict
use
antibiot
detect
infecti
agent
patient
sampl
taken
initi
visit
line
previou
studi
detect
rate
adult
describ
detect
viru
exclud
concomit
bacteri
infect
noninfecti
caus
safeti
issu
discuss
begin
studi
physician
encourag
treat
bacteri
complic
discret
sae
report
rel
larg
number
patient
lost
followup
short
durat
studi
exclud
possibl
patient
experienc
late
sae
patientrelev
outcom
sever
symptom
time
record
anoth
limit
studi
deliber
chose
includ
outcom
primari
object
studi
evalu
impact
antibiot
prescript
rate
initi
visit
studi
design
also
reduc
resourc
need
conduct
studi
analysi
crp
frequent
use
discrimin
viral
bacteri
infect
prescript
rate
increas
rise
crp
level
group
patient
crp
level
mgl
approxim
onethird
carri
respiratori
viru
support
need
reliabl
tool
aetiolog
diagnosi
arti
distinguish
viral
bacteri
aetiolog
arti
difficult
clinic
ground
alon
predict
valu
vital
sign
crp
xray
find
low
procalcitonin
pct
proven
use
reduc
antibiot
prescript
hospitalis
patient
lower
rti
wherea
primari
care
evid
pct
purpos
ambigu
one
studi
adult
arti
one
twentyeight
day
ill
durat
judg
need
antibiot
treat
outpati
report
posit
effect
antibiot
use
anoth
studi
children
communityacquir
pneumonia
signific
proport
treat
hospit
show
neg
effect
distinct
pattern
symptom
could
guid
clinician
toward
correct
aetiolog
diagnosi
identifi
studi
vomit
independ
variabl
predict
antibiot
use
may
interpret
sign
seriou
ill
justifi
antibiot
treatment
reduc
unnecessari
use
antibiot
treatment
patient
arti
utmost
import
accomplish
use
singl
strategi
patientand
physicianori
educ
programm
could
play
import
role
previous
suggest
howev
programm
solv
issu
lack
aetiolog
diagnosi
import
adequ
use
antibiot
also
address
issu
possibl
complic
prognosi
antivir
treatment
option
surveil
infect
control
conclus
shown
access
multiplex
rtpcr
assay
aetiolog
diagnosi
arti
may
reduc
prescript
rate
antibiot
initi
visit
outpati
set
sustain
effect
seem
necessari
defin
follow
manag
patient
accord
result
test
warrant
investig
believ
implement
similar
method
routin
clinic
care
may
use
tool
reduc
overprescript
antibiot
patient
arti
